Publication

Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development

A new paper argues context of use, not NAMs-versus-animals, should govern nonclinical strategy in drug…

Danielle PillsburySeptember 9, 2026

Live Events

Tailwinds for MIDD: EMA, FDA, and a Converging Regulatory Landscape

October 29, 2026 - 11:00 PM – 2:00 PM

CertaraSeptember 9, 2026

Guide

From Models to Decisions: Building MIDD Readiness in the Era of ICH M15

Explore what ICH M15 means for Model-Informed Drug Development and learn how to build MIDD…

Rik de GreefSeptember 9, 2026

Publication

A glimpse into the future of model-informed drug discovery and development

Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…

CertaraAugust 28, 2026

Publication

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

Explore how model-based tumor growth inhibition metrics can support earlier Go/No-Go decisions and pivotal trial…

CertaraAugust 28, 2026

Case Study

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…

Danielle PillsburyAugust 28, 2026

Blog

The five drug development questions that bring sponsors to pharmacometrics

Sponsors rarely come to pharmacometrics because they need a model. They come with a development…

Rik de GreefAugust 24, 2026

Webinar

Beyond Trial and Error: Model-Informed Formulation Development in Practice

Siri Kalyan ChirumamillaAugust 24, 2026

Fact Sheet

Model-Based Meta-Analysis (MBMA): Real-World Examples

See real-world examples of how model-based meta-analysis (MBMA) uses existing clinical evidence to predict trial…

CertaraAugust 24, 2026

Blog

MBMA data curation: How AI and expert meta-analysts get it right, fast

In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…

Matt Zierhut, PhD MBAAugust 14, 2026

Model Informed Drug Development

Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development

Tailwinds for MIDD: EMA, FDA, and a Converging Regulatory Landscape

From Models to Decisions: Building MIDD Readiness in the Era of ICH M15

A glimpse into the future of model-informed drug discovery and development

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

The five drug development questions that bring sponsors to pharmacometrics

Beyond Trial and Error: Model-Informed Formulation Development in Practice

Model-Based Meta-Analysis (MBMA): Real-World Examples

MBMA data curation: How AI and expert meta-analysts get it right, fast

Newsletter sign up

Quick links

Solutions

Contact